Pan cancer oncolytic vectors and methods of use thereof

Details Pan cancer oncolytic vectors and methods of use thereof Pan cancer oncolytic vectors and methods of use thereof

2008-12-04

2010-12-28

Bertoglio, Valarie (Department: 1632)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093210, C536S023100

Reexamination Certificate

active

07858083

ABSTRACT:
Replication-competent adenoviral vectors which selectively replicate in cancer cells are provided. The replication-competent viral vectors comprise an E2F responsive promoter and/or a telomerase promoter operatively linked to an adenoviral coding region. The replication-competent adenoviral vectors effectively replicate in a variety of types of cancer cells and find broad utility in the treatment of cancer.

REFERENCES:
patent: 5543328 (1996-08-01), McClelland et al.
patent: 5677178 (1997-10-01), McCormick
patent: 5698443 (1997-12-01), Henderson et al.
patent: 5731190 (1998-03-01), Wickham et al.
patent: 5756086 (1998-05-01), McClelland et al.
patent: 5801029 (1998-09-01), McCormick
patent: 5846782 (1998-12-01), Wickham et al.
patent: 5863765 (1999-01-01), Berry et al.
patent: 5871726 (1999-02-01), Henderson et al.
patent: 5922315 (1999-07-01), Roy
patent: 5962311 (1999-10-01), Wickham et al.
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 5998205 (1999-12-01), Hallenbeck et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6057155 (2000-05-01), Wickham et al.
patent: 6127525 (2000-10-01), Crystal et al.
patent: 6140087 (2000-10-01), Graham et al.
patent: 6153435 (2000-11-01), Crystal et al.
patent: 6432700 (2002-08-01), Henderson et al.
patent: 6455314 (2002-09-01), Wickham et al.
patent: 6495130 (2002-12-01), Henderson et al.
patent: 6555368 (2003-04-01), Curiel
patent: 6683170 (2004-01-01), Curiel et al.
patent: 6692736 (2004-02-01), Yu et al.
patent: 2001/0053352 (2001-12-01), Yu et al.
patent: 2003/0039633 (2003-02-01), Yu et al.
patent: 2003/0104624 (2003-06-01), Clarke et al.
patent: 2003/0104625 (2003-06-01), Cheng et al.
patent: 2003/0215948 (2003-11-01), Kaleko
patent: 2005/0095705 (2005-05-01), Kadan
patent: 0623679 (2003-06-01), None
patent: WO 95/19434 (1995-07-01), None
patent: WO 96/17053 (1996-06-01), None
patent: WO 98/07877 (1998-02-01), None
patent: WO 98/13508 (1998-04-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/39464 (1998-09-01), None
patent: WO 98/39465 (1998-09-01), None
patent: WO 98/39466 (1998-09-01), None
patent: WO 98/39467 (1998-09-01), None
patent: WO 99/06576 (1999-02-01), None
patent: WO 99/25860 (1999-05-01), None
patent: WO 99/39734 (1999-08-01), None
patent: WO 00/15820 (2000-03-01), None
patent: WO 00/46355 (2000-08-01), None
patent: WO 00/67576 (2000-11-01), None
patent: WO 01/36650 (2001-05-01), None
patent: WO 01/92299 (2001-12-01), None
patent: WO 02/067861 (2002-09-01), None
patent: WO 02/068627 (2002-09-01), None
patent: WO 2004/005511 (2004-01-01), None
Altschul et al., “Basic Local Alignment Tool”,Journal of Molecular Biology, 215:403-410 (1990).
Batzer et al., “Enhanced Evolutionary PCR Using Nucleotides with Inosine at the 3′Terminus”,Nucleic Acids Research, 19(18):5081 (1991).
Chao et al., “Assembly of the Cleavage and Polyadenylation Apparatus Requires About 10 Seconds In Vivo and is Faster for Strong than for Weak Poly(A) Sites”,Molecular and Cellular Biology, 19(8):5588-5600 (1999).
Donnelly et al., Analysis of the Apthovirus 2A2B Polyprotein ‘Cleavage’ Mechanism Indicates Not a Proteolytic Reaction, but a Novel Translational Effect: a Putative Ribosomal ‘Skip’,Molecular and Cellular Biology, 82:1013-1025 (2001).
Duke et al., “Sequence and Structural Elements That Contribute to Efficient Encephalomyocarditis Virus RNA Translation”,Journal of Virology, 66(3):1602-1609 (1992).
Dyson, “The Regulation of E2F by pRB-Family Proteins”,Genes and Development, 12:2245-2262 (1998).
Fallaux et al., “New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses”,Human Gene Therapy, 9:1909-1917 (1998).
Furler et al., Recombinant AAV Vectors Containing the Foot and Mouth Disease Virus 2A.
Sequence Confer Efficient Bicistronic Gene Expression in Cultured Cells and Rat Substantia Nigra Neurons,Gene Therapy, 8:864-873 (2001).
Graham et al., “Characteristics of a Human cell Line Transformed by DNA from human Adenovirus Type 5”,J. Gen. Virol., 36:59-72 (1977).
Gunes et al., “Expression of thehTERTGene is regulated at the Level of Transcriptional Initiation and Repressed by Mad1”,Cancer Research, 60:2116-2121 (2000).
Huez et al., “Two Independent Internal Ribosome Entry Sites are Involved in Translation Initiation of Vascular Endothelial Growth Factor mRNA”,Molecular and Cellular Biology, 18(11):6178-6190 (1998).
Jackson et al, “The novel mechanism of initiation of picornavirus RNA translation,”TIBS, 15:477-483 (1990).
Jackson et al., “Internal Initiation of Translation in Eukaryotes: The Picornovirus Paradigm and Beyond”,RNA, 1(10):985-1000 (1995).
Jakubczak et al., “An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, theE2F-1promoter, and viral replication for selectivity and efficacy”,Cancer Research, 63(7):1490-1499 (2003).
Johnson et al., “Selectively Replicating Adenoviruses Targeting Deregulated E2F Activity are Potent, Systemic Antitumor Agents”,Cancer Cell, 1:325-337, 2002.
Kilian et al., “Isolation of a Candidate Human Telomerase Catalytic Subunit Gene, Which Reveals Complex Splicing Patterns in Different Cell Types”,Human Molecular Genetics, 6(12):2011-2019 (1997).
Kim et al., “Specific Association of Human Telomerase Activity with Immortal Cells and Cancer”,Science, 266:2011-2015 (1994).
Kirn et al., “Replicating Viruses as Selective Cancer Therapeutics”,Molecular Medicine Today, 2(12):519-527 (1996).
Kiyono et al., “Both Rb/p16INK4AInactivation and Telomerase Activity are Required to Immortalize Human Epithelial Cells”,Nature, 396:84-88 (1998).
Li et al., “A Hepatocellular Carcinoma-Specific Adenovirus Variant, CV890, Eliminates Distant Human Liver Tumors in Combination with Doxorubicin”,Cancer Research, 61:6428-6436 (2001).
Li et al., “Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models,”Clinical Cancer Research, 11:8845-8855 (2005).
Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins”,Journal of Molecular Biology, 48:443-453 (1970).
Noel et al., “High in vivo production of a model monoclonal antibody on adenoviral gene transfer,”Human Gene Therapy, 13(12):1483-1493 (2002).
Ohtsuka et al., “An Alternative Approach to Deoxynucleotides as Hybridization Probes by Insertion of Deoxyinosine at Ambiguous Codon Positions”,The Journal of Biological Chemistry, 260(5):2605-2608 (1985).
Palmenberg, “Proteolytic Processing of Picomoviral Polyprotein”,Annual Review of Microbiology, 44:603-623 (1990).
Parr et al., “Tumor Selective Transgene Expression in Vivo Mediated by an E2F-Responsive Adenoviral Vector”,Nature Medicine, 3(10):1145-1149 (1997).
Pearson et al., Improved Tools for Biological Sequence Comparison,PNAS, 85:2444-2448 (1988).
Puck et al., “Clonal Growth of Mammalian Cells in Vitro”, downloaded from www.jem.org. on May 5, 2005.
Rossolini et al., “Use of Deoxyinosine-Containing Primers vs. Degenerate Primers for Polymerase Chain Reaction Based on Ambiguous Sequence Information”,Molecular and Cellular Probes, 8:91-98 (1994).
Ryan et al., “Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer,”Cancer Gene Therapy, 11:555-569 (2004).
Shay et al., “A Survey of Telomerase Activity in Human Cancer”,European Journal of Cancer, 33(5):787-791 (1997).
Smith et al., “Comparison of Biosequences”,Advances in Applied Mathematics, 2:482-489 (1981).
Smith et al., “Transient Imm

Affiliated with

Also associated with

Rating

Pan cancer oncolytic vectors and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pan cancer oncolytic vectors and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pan cancer oncolytic vectors and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4217641